Operational Update
October 28, 2019 08:00 ET
|
Immutep Limited
TACTI-002 patient recruitment updateSix patients now enrolled and dosed in INSIGHT-004, 6 mg cohort completeSignificant eftilagimod alpha clinical data expected in coming months:° AIPAC Phase II -...
Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in Melanoma
October 15, 2019 08:00 ET
|
Immutep Limited
Key Trial Findings Favourable safety profile of eftilagimod alpha in combination with pembrolizumabDeep and durable responses have been observed with tumour shrinkage in 56% and 66% of patients in...
Immutep Receives A$2.5 Million R&D Tax Incentive from French Government
October 10, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Data Presentations at Upcoming Industry Conferences
October 10, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim Data
September 26, 2019 08:00 ET
|
Immutep Limited
Requisite clinical responses achieved in cohort 1 of Part A (1st line NSCLC) of TACTI-002 Phase II clinical trial to allow for recruitment of cohort 2Recruitment of cohort 2 of Part A of TACTI-002,...
Immutep to Receive £4M Milestone Payment From GSK
September 23, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Announces Japanese Patent Grant for LAG525 Antibody
September 17, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Sept. 17, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the grant of patent no. 6576962 entitled “Antibody...
Immutep Granted European Patent for Eftilagimod Alpha in Cancer
August 22, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Aug. 22, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“ or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
Immutep Completes A$6M Entitlement Offer
August 06, 2019 08:00 ET
|
Immutep Limited
SYDNEY, Australia, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”) is pleased to announce the completion of its fully underwritten pro rata...
Operational Update
July 26, 2019 08:00 ET
|
Immutep Limited
TACTI-002 patient recruitment updateThree patients now enrolled and dosed in INSIGHT-004, recruitment ongoingSignificant eftilagimod alpha clinical data expected in coming months: º AIPAC Phase II -...